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Background—Gender differences in prognosis have frequently been reported in cardiovascular disease but less so in
congenital heart disease. We investigated whether gender is associated with outcome in adult patients with congenital
heart disease.
Methods and Results—From the CONgenital CORvitia (CONCOR) national registry for adults with congenital heart
disease, 7414 patients were identified. All outcomes before entry into the registry and during subsequent follow-up were
recorded, and differences between men and women were analyzed with the underlying congenital heart defect taken into
account. Median age at the end of follow-up was 35 years (range, 17 to 91 years); 49.8% were female. No gender
difference in mortality was found. Women had a 33% higher risk of pulmonary hypertension (odds ratio [OR]1.33;
95% CI, 1.07 to 1.65; P0.01), a 33% lower risk of aortic outcomes (OR0.67; 95% CI, 0.50 to 0.90; P0.007), a
47% lower risk of endocarditis (OR0.53; 95% CI, 0.40 to 0.70; P0.001), and a 55% lower risk of an implantable
cardioverter-defibrillator (OR0.45; 95% CI, 0.26 to 0.80; P0.006). Furthermore, the risk of arrhythmias appeared to
be lower in women (OR0.88; 95% CI, 0.77 to 1.02; P0.08).
Conclusions—The risk of several major cardiac outcomes in adult patients with congenital heart disease appears to vary
by gender. (Circulation. 2008;118:26-32.)
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More than 95% of children with congenital heartdefects now reach adulthood,1 and the number of
adults with congenital heart disease is estimated to be at
least 1.2 million in Europe alone.2 Despite major develop-
ments in diagnostic methods and treatment of congenital
heart disease, cure is rarely achieved. A vast proportion of
patients experience mild to life-threatening complications,
for which lifelong medical surveillance is required.3,4
Abundant evidence exists regarding gender differences in
the incidence of congenital heart defects at birth,5,6 but the
impact of gender on the prognosis in adult congenital heart
disease is unclear.7
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We used the Dutch nationwide CONgenital CORvitia
(CONCOR) registry for adults with congenital heart disease
to investigate whether there is an association between gender
and outcome in adult patients with congenital heart disease.
Methods
Study Subjects
The CONCOR national registry database has been described in
detail.8 Briefly, CONCOR aims to facilitate research on the etiology
of congenital heart disease and its outcome. Between January 2002
and January 2008,8600 patients with congenital heart disease aged
16 years have been included in the registry. Every year, nearly
1500 patients are added. Clinical data such as main diagnosis, other
diagnoses, clinical events and procedures, and patient and family
history are obtained from each patient by research nurses. Patients
are contacted through their treating cardiologist or advertisements in
local media. Diagnoses, procedures, and clinical events are classified
with the use of the European Pediatric Cardiac Code Short List
coding scheme.9 In case of multiple diagnoses in 1 patient, a
prespecified hierarchical scheme founded on consensus-based clas-
sification of severity of diagnoses10 is used, by means of which the
most complex diagnosis or the diagnosis that is expected to have the
most serious sequel in the future is established as the main diagnosis.
For example, in a patient with an aortic coarctation and a bicuspid
aortic valve or with an aortic coarctation and atrial septal defect,
aortic coarctation is considered the main diagnosis. After entry into
the database, data on major cardiac events are systematically
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recorded from medical letters on patients’ condition written by their
treating cardiologist to the family practitioner and entered into the
database by 3 independent, permanently employed research nurses.
This recording is done in a systematic fashion. A regular quality
control is performed on the registry by the research nurses. Cur-
rently, 94 hospitals are participating, including all 8 tertiary referral
centers from which 6000 patients (70%) originate.
From the CONCOR database, the following patient characteristics
were obtained: gender, date of birth, age at the time of data extraction
(January 3, 2007), and the main congenital heart diagnosis. More-
over, for each patient the occurrence of outcomes before entry into
the registry and during subsequent follow-up (median, 2.7 years from
registration [2.8 years in men, 2.5 years in women]) was recorded.
The following outcomes were considered clinically important in
adult congenital heart disease1: all-cause death and age at death,
pulmonary hypertension (both pulmonary arterial and venous hyper-
tension), systemic hypertension, aortic outcomes (aneurysm, dissec-
tion, and aortic surgery), cerebrovascular accident or transient
ischemic attack, endocarditis, pacemaker implant, implantable
cardioverter-defibrillator (ICD) implant, and supraventricular and
ventricular arrhythmias. Supraventricular arrhythmias comprised the
following rhythm disturbances: sick sinus, flutter, fibrillation, and all
other forms of tachycardia, except premature atrial complexes.
Rhythm disturbances at the level of atrioventricular junction include
nodal tachycardias and reentry tachycardias, except for Wolff-
Parkinson-White and accessory pathways. Ventricular arrhythmias
consisted of flutter, fibrillation, sustained and nonsustained
tachycardias, and cardiac arrest but did not include premature
ventricular complexes. Aneurysm was defined as dilatation of the
aortic root and ascending aorta 3.7 cm and dilatation of the
descending aorta 3.0 cm. Indications for aortic surgery were either
elective (diameter of the aorta of 5.5 cm; diameter of 5.0 cm if there
was a family history of aortic dissection, when valve-sparing
surgery was planned, or in case of rapid aneurysm growth) or
acute surgery because of an aortic rupture or dissection. Systolic
pulmonary pressure was estimated on the basis of echocardiographic
evaluation (tricuspid regurgitation jet velocity measurements) be-
cause invasive data were generally not available. The most recently
recorded pulmonary arterial pressure value was used. Pulmonary
arterial hypertension was defined as a systolic pulmonary pressure
40 mm Hg.11 Pulmonary hypertension was considered to be
Eisenmenger syndrome after shunt reversal of the original systemic-
to-pulmonary shunt, accompanied by cyanosis.
Data Analysis
Outcome frequencies were calculated by congenital heart defect and
by gender.
To examine the association between gender and outcome with
adjustment for underlying heart defect, each defect occurring 5
times within an outcome (or, if the total frequency of an outcome
surpassed 200, each defect occurring 10 times) was considered in
both main and subgroup analyses. The rationale for this selection
was the need to find a balance between the inclusion of many types
of congenital heart disease to adjust for within each outcome and
optimal statistical power. Choosing an occurrence of 5 dramati-
cally decreased statistical power and led to wide confidence intervals
(CIs) for the individual diagnosis dummy variables, whereas a
threshold well 5 rendered fewer defects to adjust for and thus less
accuracy. For outcomes 200, however, a threshold of 5 yielded a
surplus of types of congenital heart disease, and therefore the number
of 10 was chosen. Each congenital heart defect selected for a
particular outcome was included in the analyses of that outcome as
an individual dummy category. All types of congenital heart disease
underlying the outcome 5 times were taken together as 1 reference
category in logistic regression analyses. Thus, for every outcome, a
specific model was created with different dummy variables. For
example, the model for aortic outcomes comprised dummy variables
of the following types of congenital heart disease: aortic coarctation,
aortic stenosis, bicuspid aortic valve, Marfan syndrome, ventricular
septal defect, and a reference category.
On the basis of current medical literature, we hypothesized congenital
heart disease to be a confounder in the association of gender and
outcome, as opposed to an effect modifier. Because the data reflected
the cumulative incidence of outcomes registered at adulthood, we used
logistic regression analysis. Logistic regression was used with each
outcome (yes/no) as outcome and gender as predictor. All analyses were
adjusted for age and subsequently adjusted for type of congenital heart
defect. For pulmonary hypertension, aortic outcomes, and arrhythmias,
the data allowed for clinically meaningful subgroup analyses. In patients
with pulmonary hypertension, diagnoses predisposing to pulmonary
arterial hypertension11 were distinguished from other diagnoses, which
were hence considered to bear the risk of pulmonary venous hyperten-
sion. Aortic outcomes were classified as aortic aneurysm, dissection,
and aortic surgery. Subjects with multiple outcomes appear in 1
analysis. Age at death and age at closure were compared for men and
women with an independent samples t test for comparison of means.
Analyses on age at closure were performed for atrial septal defect and
ventricular septal defect, separately. Analyses on atrial and ventricular
septal defect closure were performed with a Pearson 2 test for
comparison of proportions. Included in these analyses were subjects
primarily diagnosed with an atrial septal defect or ventricular septal
defect, thus excluding those with a concomitant ventricular septal defect
or atrial septal defect, respectively, because a separate analysis on
closure was performed within both defects. Results were expressed as
odds ratios (ORs) and 95% CIs, and 2-sided probability values were
calculated for effect estimates. Analyses were performed with SPSS
version 14.0 (SPSS Inc, Chicago, Ill).
The authors had full access to and take full responsibility for
the integrity of the data. All authors have read and agree to the
manuscript as written.
Results
Of 7414 subjects registered at the time of analysis, 3724
(50.2%) were male and 3690 (49.8%) were female. Median
age of men was 34.2 years (range, 17.0 to 91.4) and of women
was 36.0 years (range, 16.6 to 91.2). Patients with transpo-
sition of the great arteries, pulmonary atresia, atrioventricular
septal defect, and tricuspid atresia had a median age 30
years. Patients with atrial septal defect, Ebstein’s anomaly,
patent arterial duct, and mitral valvar prolapse had a median
age40 years. Mean age at closure of atrial septal defect was
higher in women (24.6 years) than in men (22.2 years), but
this difference did not reach statistical significance (P0.09).
Figure 1 illustrates the distribution of diagnoses. Atrial
septal defect, ventricular septal defect, tetralogy of Fallot,
aortic coarctation, and aortic stenosis collectively accounted
for 60% of all diagnoses.
The Table shows the absolute numbers of congenital heart
defects and the relative frequencies among women. Patent
arterial duct, atrial septal defect, and pulmonary atresia occurred
predominantly in women, whereas aortic stenosis, bicuspid
aortic valve, and transposition of the great arteries were more
common in men. Closure of atrial septal defects occurred
equally often in men and women (P0.42); the relative propor-
tions of closure in male and female patients with an atrial septal
defect were 73.4% and 71.2%, respectively. However, closure of
ventricular septal defects was more common in men (P0.04);
the relative proportions of closure in men and women with a
ventricular septal defect were 39.6% and 33.4%, respectively.
Additionally, the Table displays the frequency of outcomes by
type of congenital heart defect. Among 161 deceased patients,
12 deceased patients had Eisenmenger syndrome, 7 of whom
were women.
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Figure 2 shows the percentages of men and women with
each outcome. Pulmonary hypertension appears to be more
frequent in women, with aortic outcomes, endocarditis, and
ICD implant more common in men.
Figure 3 shows the ORs of outcomes for women after
adjustment for age and after additional adjustment for under-
lying congenital heart defects. Although absolute mortality
risks were not significantly different, median age at death in
women was 48 years, whereas median age at death in men
was 43 years (P0.04). Women had a 33% higher risk of
pulmonary hypertension, a 33% lower risk of aortic out-
comes, a 47% lower risk of endocarditis, and a 55% lower
risk of ICD implant (all P0.05). In addition, women had a
borderline significant 12% lower risk of arrhythmias. Adjust-
ment for underlying congenital heart defects did not materi-
ally change the results.
Figure 4 shows analyses in subsets of other outcomes after
adjustment for age and adjustment for underlying congenital
heart defects. Among patients with pulmonary hypertension,
there were 360 patients (91%) with defects predisposing to
pulmonary arterial hypertension and 36 patients (9%) with
defects predisposing to pulmonary venous hypertension. Among
those predisposing to pulmonary arterial hypertension, women
had a borderline significant 25% higher risk of pulmonary
arterial hypertension compared with men. Among Eisenmenger
patients (n95; not in the Table), gender distribution was
approximately equal (54% female; P0.20). In aortic outcomes,
aneurysms developed in 98 patients (42%), dissections occurred
in 51 patients (22%), and aortic surgery was performed in 156
patients (68%). Women had a 30% lower probability of aortic
surgery. Moreover, 1125 patients (93%) suffered from supraven-
tricular arrhythmias and 163 patients (13%) from ventricular
arrhythmias. Women had a borderline significant 12% lower risk
of supraventricular arrhythmias.
Discussion
The present study demonstrates a strong association between
gender and the risk of several outcomes in adult congenital
heart disease. Women were at higher risk for pulmonary
hypertension and at lower risk for aortic outcomes, endocar-
ditis, and ICD implant.
Certain limitations of our study need to be addressed. Be-
cause most patients originate from tertiary referral centers,
patients with complex and thus complicated congenital heart
disease may be overrepresented. However, we have no reason to
suspect that the association between gender and outcomes would
differ between patients with mild and complex congenital heart
disease. Moreover, the association of gender with outcomes may
be a reflection of gender-linked patient characteristics not
included in the CONCOR database, such as lifestyle factors or
comorbid conditions. Although we cannot exclude the possibil-
ity that some of these factors play a role in our results, this would
not explain the different directions of our findings. Finally, the
CONCOR database is not composed of patients with very mild
congenital heart disease or patients with critical congenital heart
disease who died before enrollment. Particular strengths of our
study are the large number of patients and the rigorous and
uniform methods of recording data.
Gender disparities have been documented extensively in
various fields of cardiovascular disease such as ischemic
heart disease, heart failure, and stroke. Women have a
distinctive clinical manifestation and outcome and appear to
be underinvestigated, underdiagnosed, and undertreated.12
Figure 1. Proportional distribution of
main diagnoses among study subjects
(n7414). ASD indicates atrial septal
defect (17%); VSD, ventricular septal
defect (14%); ToF, tetralogy of Fallot
(11%); CoA, aortic coarctation (10%);
AoS, aortic stenosis (8%); PS, pulmo-
nary stenosis (7%); BAV, bicuspid aortic
valve (6%); Marfan, Marfan syndrome
(5%); TGA, transposition of the great
arteries (5%); PA, pulmonary atresia
(2%); AVSD, atrioventricular septal
defect (2%); Ebstein, Ebstein’s anomaly
(2%); and Other, other congenital heart
defects (11%).
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However, evidence on gender differences in adult congenital
heart disease is scarce.
Several factors may account for the observed gender differ-
ences in cardiovascular disease. One aspect likely to play a role
is the biological distinction between men and women. Women
have smaller arteries and more frequently develop endothelial
and smooth cell dysfunction.13 Female response to pharmaceu-
tical therapy may differ because of endogenous hormone levels,
a lower body weight, a higher proportion of body fat, and a
lower glomerular filtration rate.14,15 Another potential influence
is the gender difference in clinical manifestation of cardiovas-
cular disease because common symptoms are often less pro-
nounced in women. Additionally, women have been reported to
be more willing to undergo certain procedures.16 However, this
was shown not to influence gender disparities in use of cardiac
procedures.16,17 A third modifying factor is the physician’s
perception that women are at lower risk for cardiovascular
complications than men, leading to reduced attention to early
signs and symptoms of complications in women. As a result,
women with cardiovascular disease may be treated less opti-
mally, a phenomenon known as gender bias or the Yentl
syndrome.18 Studies addressing the impact of the physician’s
perception have yielded conflicting results.19,20 Finally, the lack
of gender-specific thresholds of diagnostic procedures in cardio-
vascular disease may render distorted detection rates of cardiac
complications in either gender.
In congenital heart disease, numerous defects exhibit an
association with gender at birth. Defects mainly involving the
inflow tract of the heart such as atrial septal defect and
Ebstein’s anomaly prevail in females, whereas outflow tract
defects such as aortic stenosis and transposition of the great
arteries predominate in males.5,6 In the CONCOR database,
the gender distribution of adults with congenital heart disease
resembles the gender distribution at birth. This finding, which
has been reported previously,7,21 supports the hypothesis that
overall mortality during childhood is not influenced by
gender, a phase not covered by CONCOR.
In our study, no gender difference was found in mortality
during the period of follow-up. However, a higher mortality in
men with congenital heart disease has been reported.22 In
children, sudden cardiac death is more frequent in boys,23 yet
mortality ensuing surgery for congenital heart disease is more
common in girls.24 In coronary heart disease, evidence on gender
disparities in mortality after revascularization is conflicting.25–27
Additionally, female mortality has been reported to be higher
after valvular surgery28 but lower in heart failure.29
We found women to be at higher risk for pulmonary
arterial hypertension. This agrees with previous findings7 and
may reflect hormonal differences in general and the burden of
pregnancy in particular because this potentially has deleteri-
ous effects in congenital heart disease.7,30 We found no
difference in gender distribution of Eisenmenger syndrome,
as in the Euro Heart Survey,31 suggesting equal progression
of pulmonary arterial hypertension.
In our study, women were at lower risk for aortic out-
comes, which was largely due to lower rates of aortic surgery.
Because the female aorta is significantly smaller32 and criteria
for elective aortic surgery are not gender specific, men are
Table. Frequency of Several Major Outcomes in Underlying Congenital Heart Defects in All Patients (n7414)
Frequency Outcome
Defect Total, n Female, % Death
Pulmonary
Hypertension
Systemic
Hypertension
Aortic
Outcomes CVA/TIA Endocarditis Pacemaker ICD Arrhythmia
Atrial septal defect 1267 62 28 93 70 3 68 10 81 6 344
Ventricular septal defect 1061 55 10 87 45 15 16 54 38 6 89
Tetralogy of Fallot 791 44 21 21 13 5 16 29 49 27 173
Aortic coarctation 756 40 7 26 171 38 13 15 10 1 45
Aortic stenosis 571 35 10 6 32 30 10 21 18 1 47
Pulmonary stenosis 549 58 5 7 23 1 9 2 7 0 39
Bicuspid aortic valve 419 34 5 5 39 28 11 29 13 2 33
Marfan syndrome 380 50 6 0 18 96 8 7 2 0 24
TGA 378 34 8 25 1 0 9 10 66 8 127
Pulmonary atresia 136 60 9 13 1 2 3 14 3 0 17
AVSD 125 59 6 50 0 0 0 7 5 1 12
Ebstein’s anomaly 125 56 6 3 9 0 5 2 8 1 52
UVH/DILV 99 45 10 15 2 0 7 6 16 0 44
cc-TGA 96 38 6 4 1 0 1 7 27 0 35
Patent arterial duct 94 84 2 4 9 1 2 0 2 0 14
Mitral valvar prolapse 71 51 2 0 2 1 3 4 2 2 15
Tricuspid atresia 65 49 9 2 0 0 4 4 9 0 32
Other defects 431 55 11 35 18 11 14 13 28 5 70
All defects 7414 50 161 396 454 231 199 234 384 60 1212
CVA indicates cerebrovascular accident; TIA, transient ischemic attack; TGA, transposition of the great arteries; AVSD, atrioventricular septal defect; UVH,
univentricular heart; DILV, double-inlet left ventricle; and cc-TGA, congenitally corrected transposition of the great arteries. Other defects comprise those defects with
a total frequency below n65. Subjects with multiple outcomes appear in 1 column.
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expected to reach the threshold for elective surgery earlier
than women. In addition, in atherosclerotic disease, men are
more likely to undergo aortic surgery,33 although fatal rup-
tures are more common in women.34 Worse surgical outcome
and higher mortality in women have also been observed in
acute dissection.35 These findings may suggest inadequate
diagnosis and treatment of aortic aneurysms in women.
Women were at lower risk for endocarditis, similar to reports
on adults without congenital heart disease.36 This may reflect
differences in lifestyle factors such as poor oral hygiene37 and
intravenous drug abuse,38 both of which are more common in
men. However, gender differences in knowledge of endocarditis
prevention such as antibiotic prophylaxis or need for optimal
dental and skin care have not been reported.39 Furthermore, the
Figure 2. Percentages of outcomes in
men (n3724) and women (n3690).
Percentages are not adjusted for age
and underlying congenital heart defects.
CVA indicates cerebrovascular accident;
TIA, transient ischemic attack.
Figure 3. ORs of outcomes in women
compared with men. The gray lines rep-
resent ORs with 95% CIs adjusted for
age only. The black lines represent ORs
with 95% CIs additionally adjusted for
underlying congenital heart defects. The
numbers adjacent to the figure corre-
spond to the black lines. CVA indicates
cerebrovascular accident; TIA, transient
ischemic attack.
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gender difference in risk for endocarditis might have been
influenced by gender differences in closure of ventricular septal
defects, a diagnosis frequently underlying endocarditis. If so,
however, we would have expected the risk for endocarditis to be
lower in men because ventricular septal defects were closed
more often in men compared with women.
We found a lower risk of ICD implant and a slightly lower
risk of (mainly supraventricular) arrhythmias in women. No
gender difference was found in ventricular arrhythmias, a
major indication for ICD implant. The lower ICD implant rate
in women may result from gender bias, which has been
reported previously in coronary heart disease.40 Of note,
gender differences in events after ICD implant have not been
described,40,41 implying an equal benefit from ICD implant.
The current literature shows a considerable impact of
gender on outcome within the scope of cardiovascular dis-
ease. Extending this evidence to congenital heart disease, we
believe our results to be hypothesis generating on the role of
gender. This should stimulate basic and clinical research to
advance the knowledge on gender-specific issues.
In conclusion, the results of the present study support the
view that the risk of several major cardiac outcomes in adult
congenital heart disease appears to vary by gender.
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CLINICAL PERSPECTIVE
Gender differences in prognosis have frequently been reported in cardiovascular disease but less so in adult congenital heart
disease. In the CONgenital CORvitia (CONCOR) national registry of adults with congenital heart disease (n7414), we
found that women had a 33% higher risk of pulmonary hypertension, a 33% lower risk of aortic outcomes, a 47% lower
risk of endocarditis, and a 55% lower risk of an implantable cardioverter-defibrillator implant. These findings should
stimulate basic and clinical research to advance the knowledge on gender-specific issues in adult congenital heart disease.
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